Study of INT-747 in Patients With Diabetes and Presumed NAFLD
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus
(DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following:
- The safety and tolerability of multiple doses of INT 747;
- The effects of 2 dose levels (25 mg and 50 mg) of INT 747 on insulin resistance and
glucose homeostasis;
- Effects of INT-747 on hepatocellular function as measured by assessment of liver enzymes
and biochemical markers of hepatic and metabolic function and inflammation, and;
- Trough concentrations of INT-747 and its metabolites, glyco 6-ethyl chenodeoxycholic
acid (6-EDCA) and tauro 6-ECDCA.